...

Expert Analysis

Antiretroviral Resistance, Treatment Interruptions, & Salvage Therapy

Source: CCO Independent Conference Coverage of the 2003 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Antiretroviral Resistance, Treatment Interruptions, & Salvage Therapy


Program Director: John P. Phair, MD

Faculty:

Joel E. Gallant, MD, MPHWilliam A. O'Brien, MD, MSAndrew R. Zolopa, MD
  • Joel E. Gallant, MD, MPH
  • William A. O'Brien, MD, MS
  • Andrew R. Zolopa, MD

CREDIT INFORMATION

Release Date: March 06, 2003

Expiration Date: March 05, 2004


Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Begin the Expert Analysis

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss data on the effects of discontinuing agents comprising only part of a treatment regimen

  • Outline the likely role of T-20 and atazanavir in treatment strategies

  • Describe recent research on the possible role of treatment interruptions in patient management


Earn CME credit by reading the expert analysis and commentary on the antiretroviral management of patients receiving therapy. Topics covered include:

  • Treatment interruption and resumption based on CD4+ cell count
  • Intermittent therapy
  • Treatment interruption before starting salvage therapy
  • Partial treatment interruptions
  • T-20 as a component of salvage therapy
  • Implications of atazanavir's resistance profile
  • Resistance testing
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.